Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure—Current Evidence in Special Populations

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, originally used for diabetes mellitus, are gaining more popularity for other indications, owing to their positive cardiovascular and renal effects. SGLT2 inhibitors reduce heart failure (HF) hospitalization and improve cardiovascular outcomes in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Moady, Gassan, Ben Gal, Tuvia, Atar, Shaul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301138/
https://www.ncbi.nlm.nih.gov/pubmed/37374037
http://dx.doi.org/10.3390/life13061256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301138/
https://www.ncbi.nlm.nih.gov/pubmed/37374037
http://dx.doi.org/10.3390/life13061256

Ejemplares similares